ACE2: the molecular doorway to SARS-CoV-2

被引:78
作者
Medina-Enriquez, Miriam Marlene [1 ]
Lopez-Leon, Sandra [2 ]
Carlos-Escalante, Jose Alberto [3 ]
Aponte-Torres, Zuleika
Cuapio, Angelica [4 ]
Wegman-Ostrosky, Talia [5 ]
机构
[1] Univ Barcelona, Fac Farm, Barcelona, Spain
[2] Novartis Pharmaceut, Global Drug Dev, E Hanover, NJ USA
[3] Univ Nacl Autonoma Mexico, Fac Med, Mexico City, DF, Mexico
[4] Karolinska Inst, Ctr Infect Med, Stockholm, Sweden
[5] Inst Nacl Cancerol, Dept Basic Res, 22 San Fernando Ave,Belisario Dominguez Secc 16, Mexico City 14080, DF, Mexico
关键词
ACE2; SARS-CoV-2; COVID-19; Coronavirus; CONVERTING-ENZYME; 2; DIABETIC-NEPHROPATHY; BLOOD-PRESSURE; MESSENGER-RNA; SARS-COV; ASSOCIATION; EXPRESSION; RECEPTOR; CORONAVIRUS; COVID-19;
D O I
10.1186/s13578-020-00519-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The angiotensin-converting enzyme 2 (ACE2) is the host functional receptor for the new virus SARS-CoV-2 causing Coronavirus Disease 2019. ACE2 is expressed in 72 different cell types. Some factors that can affect the expression of the ACE2 are: sex, environment, comorbidities, medications (e.g. anti-hypertensives) and its interaction with other genes of the renin-angiotensin system and other pathways. Different factors can affect the risk of infection of SARS-CoV-2 and determine the severity of the symptoms. The ACE2 enzyme is a negative regulator of RAS expressed in various organ systems. It is with immunity, inflammation, increased coagulopathy, and cardiovascular disease. In this review, we describe the genetic and molecular functions of the ACE2 receptor and its relation with the physiological and pathological conditions to better understand how this receptor is involved in the pathogenesis of COVID-19. In addition, it reviews the different comorbidities that interact with SARS-CoV-2 in which also ACE2 plays an important role. It also describes the different factors that interact with the virus that have an influence in the expression and functional activities of the receptor. The goal is to provide the reader with an understanding of the complexity and importance of this receptor.
引用
收藏
页数:17
相关论文
共 140 条
[51]   ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation [J].
Hashimoto, Tatsuo ;
Perlot, Thomas ;
Rehman, Ateequr ;
Trichereau, Jean ;
Ishiguro, Hiroaki ;
Paolino, Magdalena ;
Sigl, Verena ;
Hanada, Toshikatsu ;
Hanada, Reiko ;
Lipinski, Simone ;
Wild, Birgit ;
Camargo, Simone M. R. ;
Singer, Dustin ;
Richter, Andreas ;
Kuba, Keiji ;
Fukamizu, Akiyoshi ;
Schreiber, Stefan ;
Clevers, Hans ;
Verrey, Francois ;
Rosenstiel, Philip ;
Penninger, Josef M. .
NATURE, 2012, 487 (7408) :477-U89
[52]   High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study [J].
Helms, Julie ;
Tacquard, Charles ;
Severac, Francois ;
Leonard-Lorant, Ian ;
Ohana, Mickael ;
Delabranche, Xavier ;
Merdji, Hamid ;
Clere-Jehl, Raphael ;
Schenck, Malika ;
Fagot Gandet, Florence ;
Fafi-Kremer, Samira ;
Castelain, Vincent ;
Schneider, Francis ;
Grunebaum, Lelia ;
Angles-Cano, Eduardo ;
Sattler, Laurent ;
Mertes, Paul-Michel ;
Meziani, Ferhat .
INTENSIVE CARE MEDICINE, 2020, 46 (06) :1089-1098
[53]   Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 [J].
Hoffmann, Markus ;
Schroeder, Simon ;
Kleine-Weber, Hannah ;
Mueller, Marcel A. ;
Drosten, Christian ;
Poehlmann, Stefan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)
[54]  
Hoffmann Markus, 2020, bioRxiv, DOI [10.1016/j.ebiom.2021.103255, 10.1101/2020.08.05.237651]
[55]   Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 [J].
Horby, Peter ;
Mafham, Marion ;
Linsell, Louise ;
Bell, Jennifer L. ;
Staplin, Natalie ;
Emberson, Jonathan R. ;
Wiselka, Martin ;
Ustianowski, Andrew ;
Elmahi, Einas ;
Prudon, Benjamin ;
Whitehouse, Tony ;
Felton, Timothy ;
Williams, John ;
Faccenda, Jakki ;
Underwood, Jonathan ;
Baillie, J. Kenneth ;
Chappell, Lucy C. ;
Faust, Saul N. ;
Jaki, Thomas ;
Jeffery, Katie ;
Lim, Wei Shen ;
Montgomery, Alan ;
Rowan, Kathryn ;
Tarning, Joel ;
Watson, James A. ;
White, Nicholas J. ;
Juszczak, Edmund ;
Haynes, Richard ;
Landray, Martin J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21) :2030-2040
[56]   Obesity and COVID-19: ACE 2, the Missing Tile [J].
Iannelli, Antonio ;
Favre, Guillaume ;
Frey, Sebastien ;
Esnault, Vincent ;
Gugenheim, Jean ;
Bouam, Samir ;
Schiavo, Luigi ;
Tran, Albert ;
Alifano, Marco .
OBESITY SURGERY, 2020, 30 (11) :4615-4617
[57]   PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMOSTAT MESILATE .5. EFFECTS ON THE PANCREATIC-ENZYMES AND EXPERIMENTAL ACUTE-PANCREATITIS IN RATS [J].
IWAKI, M ;
INO, Y ;
MOTOYOSHI, A ;
OZEKI, M ;
SATO, T ;
KURUMI, M ;
AOYAMA, T .
JAPANESE JOURNAL OF PHARMACOLOGY, 1986, 41 (02) :155-162
[58]   Monoclonal antibody as a potential anti-COVID-19 [J].
Jahanshahlu, Leila ;
Rezaei, Nima .
BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
[59]   Circulating ACE2 activity correlates with cardiovascular disease development [J].
Katalin, Uri ;
Miklos, Fagyas ;
Attila, Kertesz ;
Attila, Borbely ;
Csaba, Jenei ;
Orsolya, Bene ;
Zoltan, Csanadi ;
Walter, J. Paulus ;
Istvan, Edes ;
Zoltan, Papp ;
Attila, Toth ;
Erzsebet, Lizanecz .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2016, 17 (04)
[60]   Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry [J].
Kawase, Miyuki ;
Shirato, Kazuya ;
van der Hoek, Lia ;
Taguchi, Fumihiro ;
Matsuyama, Shutoku .
JOURNAL OF VIROLOGY, 2012, 86 (12) :6537-6545